ImmuCell Corporation (Nasdaq: ICCC), an animal health biologics company, has announced the appointment of Kathy Turner to its Board of Directors, effective April 1, 2026. Turner replaces Steven Rosgen, who is retiring from the Board after serving since January 2018. With over three decades of experience in global healthcare and animal health markets, Turner has previously held senior leadership roles at IDEXX Laboratories and served on the Board of Elanco Animal Health. Her extensive background is expected to enhance the Board's capabilities as ImmuCell seeks to expand its product offerings, particularly the First Defense product line, which provides immediate immunity to calves against common diseases. The company expressed gratitude for Rosgen's contributions during his tenure. This leadership change is anticipated to positively influence the company's strategic direction and operational execution.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.